Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRC | Q99895 | 1/20 | 0.32 |
| ▸ | CD4 | P01730 | 2/20 | 0.30 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP7 | P09237 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | MMP12 | P39900 | 1/20 | 0.30 |
| ▸ | MMP14 | P50281 | 1/20 | 0.30 |
| ▸ | MMP15 | P51511 | 1/20 | 0.30 |
| ▸ | MMP16 | P51512 | 1/20 | 0.30 |
| ▸ | MMP26 | Q9NRE1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14716061 | 1.00 | CTRC (0.32) | CTRCCD4MMP1MMP2MMP7 | |
| SCHEMBL14716060 | 1.00 | CTRC (0.32) | CTRCCD4MMP1MMP2MMP7 | |
| SCHEMBL14715871 | 0.86 | CYP4F2 (0.32) | — | |
| SCHEMBL20218870 | 0.86 | CYP4F2 (0.32) | — | |
| SCHEMBL14715868 | 0.86 | CYP4F2 (0.32) | — | |
| SCHEMBL14715869 | 0.86 | CYP4F2 (0.32) | — | |
| SCHEMBL14715919 | 0.78 | MEN1 (0.33) | — | |
| SCHEMBL20218704 | 0.78 | BCHE (0.31) | — | |
| SCHEMBL14715917 | 0.78 | MEN1 (0.33) | — | |
| SCHEMBL14716101 | 0.78 | BCHE (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2581361-B1 | Intermediates for the synthesis of benzindene prostaglandins and preparations thereof | CHIROGATE INT INC (TW) | 2018-06-06 | — | — | EP | disclosed |
| US-8658837-B2 | Intermediates for the synthesis of benzindene prostaglandins and preparations thereof | CHIROGATE INTERNATIONAL INC. (TW) | 2014-02-25 | — | — | US | disclosed |
| US-8524939-B2 | Intermediates for the synthesis of benzindene prostaglandins and preparations thereof | CHIROGATE INTERNATIONAL INC. (TW) | 2013-09-03 | — | — | US | disclosed |
| EP-2581361-A1 | Intermediates for the synthesis of benzindene prostaglandins and preparations thereof | Chirogate International Inc. (TW) | 2013-04-17 | — | — | EP | disclosed |
| US-20130053581-A1 | INTERMEDIATES FOR THE SYNTHESIS OF BENZINDENE PROSTAGLANDINS AND PREPARATIONS THEREOF | CHIROGATE INTERNATIONAL INC. | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053581-A1 | INTERMEDIATES FOR THE SYNTHESIS OF BENZINDENE PROSTAGLANDINS AND PREPARATIONS THEREOF | PTGIS, PTGES, PTGS1 | CTRC 1624/4885CD4 3760/4885MMP1 1672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.